Tearsheet

Aktis Oncology (AKTS)

Market Price (6/13/2026): $21.93 | Market Cap: $1.1 BilSector: Health Care | Industry: Biotechnology

Aktis Oncology (AKTS)

Market Price (6/13/2026): $21.93
Market Cap: $1.1 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -49%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.

Trading close to highs
Dist 52W High is -2.1%, Dist 3Y High is -2.1%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -74 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -988%

Expensive valuation multiples
P/SPrice/Sales ratio is 143x

Stock price has recently run up significantly
6M Rtn6 month market price return is 9223372036854775807%, 12M Rtn12 month market price return is 21929900%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 86%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -933%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1069%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 9223372036854775807%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.9%

High stock price volatility
Vol 12M is 311%

Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.39

Key risks
AKTS key risks include [1] its heavy dependence on a limited, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -49%
1	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.
2	Trading close to highs Dist 52W High is -2.1%, Dist 3Y High is -2.1%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -74 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -988%
4	Expensive valuation multiples P/SPrice/Sales ratio is 143x
5	Stock price has recently run up significantly 6M Rtn6 month market price return is 9223372036854775807%, 12M Rtn12 month market price return is 21929900%
6	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 86%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -933%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1069%
8	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 9223372036854775807%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.9%
10	High stock price volatility Vol 12M is 311%
11	Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.39
12	Key risks AKTS key risks include [1] its heavy dependence on a limited, Show more.

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	6/13/26	2025	2024	2023	2022
Share Price			$21.93	$0.00	$0.00	$0.83	$2.82
Mkt Cap ($ Bil)			1.1	0.0	-	-	-
+ Debt ($ Bil)			0.0	0.0	0.0	0.0	0.0
- Cash ($ Bil)			0.5	0.2	0.0	0.0	0.0
TEV ($ Bil)			0.5	0.0
Valuation Ratios
P/S	71.8	51.4	142.6	0.0	-	-	-
P/EBIT	—	—	-14.4	-0.0	-	-	-
P/E	—	—	-17.6	-0.0	-	-	-
P/FCF	—	—	-13.3	-0.0	-	-	-
Sector Ratios (* = sector average)
P/S *			3.7	4.2	3.8	4.2	4.6
P/EBIT *			-1.7	-1.7	-1.5	-1.5	-1.3
P/E *			-1.8	-1.8	-1.7	-1.7	-1.3
P/FCF *			-1.8	-1.8	-1.5	-1.6	-1.6

FYE: 12/31	Forward FYE		Now
	2027	2026	6/13/26
Share Price			$21.93
Mkt Cap ($ Bil)			1.1
+ Debt ($ Bil)			0.0
- Cash ($ Bil)			0.5
TEV ($ Bil)			0.5
Valuation Ratios
P/S	71.8	51.4	142.6
P/EBIT	—	—	-14.4
P/E	—	—	-17.6
P/FCF	—	—	-13.3
Sector Ratios (* = sector average)
P/S *			3.7
P/EBIT *			-1.7
P/E *			-1.8
P/FCF *			-1.8

FYE: 12/31	AKTS [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$7.5 Mil	—
FY 2026 Sales	$20.7 Mil	—
FY 2027 Sales	$14.9 Mil	—
FY 2026 Sales Growth	177.5%	—
FY 2027 Sales Growth	-28.4%	7.8%
EARNINGS
LTM Net Income (GAAP) [3]	$-60.5 Mil	—
FY 2026 Net Income (Non-GAAP)	$-84.6 Mil	—
FY 2027 Net Income (Non-GAAP)	$-126.9 Mil	—
FY 2027 Net Income Growth	—	14.6%
FY 2026 EPS (Non-GAAP)	$-1.62	—
FY 2027 EPS (Non-GAAP)	$-2.28	—
FY 2027 EPS Growth	—	—
VALUATION
FY 2026 P/S	51.4	3.3
FY 2027 P/S	71.8	—
FY 2026 P/E	—	20.1
FY 2027 P/E	—	—

[1] AKTS forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 6/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

	AKTS	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	0.0
Rev Chg Q	�	8.8%
Rev Chg LTM	�	7.4%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-987.8%	18.4%
CFO/Rev LTM	-933.0%	21.3%
Net Inc Mgn	-809.2%	13.0%
VALUATION	VERY HIGH
P/S	142.6	3.3
P/CFO	-15.3	15.2
P/FCF	-13.3	19.7
P/E	-17.6	24.2
STABILITY	VERY GOOD
Debt/Equity	0.01	0.21
Cash/Assets	0.93	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Pipeline Programs	7	12252025	Link
Number of Patients Enrolling in Phase 1b Trial for Ac-AKY-1189	150	12192025	Link
Upfront Payment from Eli Lilly Collaboration	60 million USD	5212024	Link
Potential Milestone Payments from Eli Lilly Collaboration	1.1 billion USD	5212024	Link
Number of Patent Families	2	12252025	Link

Price Chart

Recent
6/03/2026	Earnings Release	Rev: $1.0 Mil (E) EPS: $-0.33 (E)
Upcoming
8/10/2026	Earnings Release	Rev: $2.0 Mil (E) EPS: $-0.42 (E)
9/02/2026	Earnings Release	Rev: $2.0 Mil (E) EPS: $-0.42 (E)

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/12/2026

Aktis Oncology (AKTS) stock has gained about 10% since 2/28/2026 because of the following key factors:

1. Positive regulatory milestones for key pipeline assets fueled investor confidence.

In February 2026, Aktis Oncology's lead candidate, AKY-1189, received FDA Fast Track designation for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies. Following this, in March 2026, the company announced FDA clearance of Investigational New Drug (IND) applications for AKY-2519, enabling the initiation of Phase 1b clinical trials for this B7-H3 targeted miniprotein radioconjugate.

2. Promising early clinical imaging data for AKY-2519 was presented at a major oncology conference.

Aktis Oncology presented first-in-human clinical imaging and dosimetry data for AKY-2519 at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2, 2026. The data demonstrated robust tumor uptake and limited normal tissue exposures in patients with B7-H3 expressing tumors, providing early validation for the therapeutic approach and informing the ongoing clinical development strategy for AKY-2519.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 8.9% change in AKTS stock from 2/28/2026 to 6/13/2026 was primarily driven by a 0.0% change in the company's P/E Multiple.

(LTM values as of)	2282026	6132026	Change
Stock Price ($)	20.13	21.93	8.9%
Change Contribution By:
Total Revenues ($ Mil)	�	�	0.0%
Net Income Margin (%)	�	�	0.0%
P/E Multiple	�	�	0.0%
Shares Outstanding (Mil)	35	35	0.0%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/13/2026

	Return	Correlation
AKTS	8.9%
Market (SPY)	8.4%	53.5%
Sector (XLV)	-3.6%	42.2%

Fundamental Drivers

null
null

Market Drivers

11/30/2025 to 6/13/2026

	Return	Correlation
AKTS	∞%
Market (SPY)	9.2%	�
Sector (XLV)	-1.6%	�

Fundamental Drivers

null
null

Market Drivers

5/31/2025 to 6/13/2026

	Return	Correlation
AKTS	21929900.0%
Market (SPY)	27.3%	�
Sector (XLV)	18.0%	�

Fundamental Drivers

null
null

Market Drivers

5/31/2023 to 6/13/2026

	Return	Correlation
AKTS	594.0%
Market (SPY)	84.5%	�
Sector (XLV)	26.5%	�

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
AKTS Return	-45%	-58%	-70%	-99%	-100%	∞%	-100%
Peers Return	29%	34%	13%	-0%	2%	11%	122%
S&P 500 Return	27%	-19%	24%	23%	16%	8%	97%
Monthly Win Rates [3]
AKTS Win Rate	25%	50%	50%	25%	33%	40%
Peers Win Rate	45%	60%	40%	53%	55%	60%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
AKTS Max Drawdown	-67%	-67%	-90%	-99%	-100%	-32%
Peers Max Drawdown	-38%	-31%	-47%	-52%	-43%	-26%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: LNTH, ATNM, CATX, LLY, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/12/2026 (YTD)

Event	AKTS	S&P 500
2025 US Tariff Shock
% Loss	-100.0%	-18.8%
% Gain to Breakeven	∞%	23.1%
Time to Breakeven	232 days	79 days
2024 Yen Carry Trade Unwind
% Loss	-37.4%	-7.8%
% Gain to Breakeven	59.7%	8.5%
Time to Breakeven	518 days	18 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-79.2%	-9.5%
% Gain to Breakeven	381.3%	10.5%
Time to Breakeven	802 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-34.6%	-6.7%
% Gain to Breakeven	53.0%	7.1%
Time to Breakeven	983 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-66.6%	-24.5%
% Gain to Breakeven	199.6%	32.4%
Time to Breakeven	1177 days	427 days
2020 COVID-19 Crash
% Loss	-49.1%	-33.7%
% Gain to Breakeven	96.4%	50.9%
Time to Breakeven	30 days	140 days

Compare to LNTH, ATNM, CATX, LLY, BMY

In The Past

Aktis Oncology's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	AKTS	S&P 500
2025 US Tariff Shock
% Loss	-100.0%	-18.8%
% Gain to Breakeven	∞%	23.1%
Time to Breakeven	232 days	79 days
2024 Yen Carry Trade Unwind
% Loss	-37.4%	-7.8%
% Gain to Breakeven	59.7%	8.5%
Time to Breakeven	518 days	18 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-79.2%	-9.5%
% Gain to Breakeven	381.3%	10.5%
Time to Breakeven	802 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-34.6%	-6.7%
% Gain to Breakeven	53.0%	7.1%
Time to Breakeven	983 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-66.6%	-24.5%
% Gain to Breakeven	199.6%	32.4%
Time to Breakeven	1177 days	427 days
2020 COVID-19 Crash
% Loss	-49.1%	-33.7%
% Gain to Breakeven	96.4%	50.9%
Time to Breakeven	30 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-54.3%	-19.2%
% Gain to Breakeven	118.7%	23.8%
Time to Breakeven	93 days	105 days
2015-2016 China Devaluation / Global Growth Scare
% Loss	-69.8%	-12.2%
% Gain to Breakeven	231.1%	13.9%
Time to Breakeven	306 days	62 days
2014-2016 Oil Price Collapse
% Loss	-39.6%	-6.8%
% Gain to Breakeven	65.6%	7.3%
Time to Breakeven	121 days	15 days

Compare to LNTH, ATNM, CATX, LLY, BMY

In The Past

Aktis Oncology's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Aktis Oncology (AKTS)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.

AI Analysis | Feedback

It's like Corning, but instead of making specialized glass for smartphone screens, Akoustis makes the high-performance filters essential for wireless communication in your phone and Wi-Fi.
Think of it as a specialized TSMC or GlobalFoundries, but entirely focused on designing and manufacturing advanced radio frequency filters and MEMS for wireless devices.
It's like the "Intel Inside" for wireless communication, creating the critical filter components that enable your smartphone, Wi-Fi, and other wireless tech to function reliably.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Here are the key risks to Aktis Oncology's business:

Clinical Development and Regulatory Risk: As a clinical-stage oncology company, Aktis Oncology's success is heavily dependent on the successful development, clinical trials, and regulatory approval of its product candidates, such as AKY-1189 and AKY-2519. The company's lead candidate, AKY-1189, recently received FDA Fast Track designation for advanced urothelial cancer, which can accelerate development and review but does not mitigate the inherent scientific or clinical risks. Uncertainties exist regarding the progression and safety data from ongoing trials like NECTINIUM-2 Phase 1b, and the potential for its therapies to address a broad range of tumor types beyond those initially targeted remains to be fully established.
Financial Risk and Reliance on External Funding: Aktis Oncology is currently unprofitable and is not expected to achieve profitability within the next three years, with analysts forecasting an average annual earnings decline of 25.5% over this period. The company is in an investment-heavy phase and will likely need to rely on external funding to finance its research and development activities and advance its pipeline. The ability to secure sufficient capital and manage its cash runway effectively are critical financial considerations.
Supply Chain Risk for Alpha-Emitting Isotopes: Aktis Oncology specializes in developing radiopharmaceutical therapies that utilize alpha-emitting isotopes, such as Actinium-225. The availability and consistent supply of these specialized isotopes are crucial for the development and potential commercialization of their products. Fluctuations in the supply chain or changes in the landscape of alpha-emitting isotope production could pose a risk to the company's operations and strategy.

AI Analysis | Feedback

null

AI Analysis | Feedback

Aktis Oncology (symbol: AKTS) operates in the radiopharmaceutical market, developing targeted radiopharmaceuticals for solid tumors. The company's main product candidates include AKY-1189, which targets Nectin-4 for urothelial cancer and other Nectin-4 expressing tumors, and AKY-2519, which targets B7-H3 for prostate and lung cancers. The addressable market for radiopharmaceuticals is projected to exceed **$26 billion globally by 2032**. The therapeutic segment of this market is estimated to reach **$25–$60 billion globally post-2030**. More broadly, the radiopharmaceutical market was valued at $6.2 billion in 2024 and is projected to reach $19.6 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 12.7%. Aktis Oncology's lead candidate, AKY-1189, targets Nectin-4, which is expressed in approximately 80% to 90% of urothelial cancers, indicating a significant addressable patient population if successful. Nectin-4 is also expressed in other high-incidence tumor types.

AI Analysis | Feedback

Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for solid tumors. As such, its future revenue growth over the next 2-3 years will primarily be driven by the progression of its pipeline and potential market entry of its therapeutic candidates. The key drivers are expected to be:

Advancement and Commercialization of its Miniprotein Radioconjugate Platform and Pipeline Products: Aktis Oncology's core strategy revolves around its proprietary miniprotein radioconjugate platform, designed to deliver tumor-killing radioisotopes to targeted tumors. The successful advancement of its pipeline products, such as AKY-1189, through clinical trials, regulatory approvals, and eventual commercial launch, will be the primary driver of future revenue. AKY-1189, a Nectin-4 miniprotein radioconjugate, has already received U.S. FDA Fast Track Designation for the treatment of locally advanced or metastatic urothelial cancer, which could expedite its development and review process.
Expansion into New Cancer Indications and Patient Populations: A central part of Aktis Oncology's mission is to expand the potential of targeted radiopharmaceuticals to broad patient populations, including those not currently addressed by existing technologies. The company aims to achieve this by developing next-generation technologies that broaden the spectrum of tumor targets for effective radiopharmaceutical delivery. Successfully expanding its therapies to new solid tumor types, such as breast, lung, colorectal, bladder, and liver cancers, will unlock significant new market opportunities and contribute to revenue growth.
Strategic Collaborations and Partnerships: As a clinical-stage biotechnology company, strategic collaborations and partnerships are crucial for funding research and development, mitigating risks, and accelerating market access. The company has already garnered "substantial backing from Big Pharma mainstay Eli Lilly", suggesting a precedent for such alliances. Future agreements for co-development, licensing, or commercialization of its platform or pipeline assets could provide significant upfront payments, milestone achievements, and royalties, thereby contributing to its revenue streams.

AI Analysis | Feedback

null

Interactive Breakdown

null

null

Better Bets vs. Aktis Oncology (AKTS)

null

Latest Trefis Analyses

null

Trade Ideas

Select ideas related to AKTS.

null

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ROKU	Roku	21.2	20.1%	32.4%
TBN	Tamboran Resources	0.9	19.9%	48.3%
STTK	Shattuck Labs	0.6	18.2%	35.3%
SENEA	Seneca Foods	1.2	17.5%	58.5%
ALMS	Alumis	3.0	15.6%	147.4%
ELVN	Enliven Therapeutics	2.9	14.3%	199.5%
AKTS	Aktis Oncology	1.1	12.7%	∞%
ZBIO	Zenas BioPharma	1.1	11.5%	-45.5%
POET	POET Technologies	1.8	11.4%	97.9%
VYX	NCR Voyix	1.1	10.3%	-23.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	5.1	-19.1%	42.5%
YSS	York Space Systems	3.5	-17.9%	-17.6%
VELO	Velo3D	0.5	-16.7%	85.6%
ASTS	AST SpaceMobile	24.0	-15.5%	13.5%
OMER	Omeros	0.6	-14.2%	-49.1%
VOYG	Voyager Technologies	2.4	-14.0%	57.4%
LUNR	Intuitive Machines	3.2	-13.1%	64.0%
SHAZ	SharonAI	0.9	-12.9%	-32.6%
SWMR	Swarmer	0.7	-12.7%	45.8%
NAVN	Navan	5.0	-11.9%	16.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
VELO	Velo3D	0.5	60.9%	85.6%
TNGX	Tango Therapeutics	4.4	53.0%	249.2%
CBRL	Cracker Barrel Old Country Store	1.0	39.2%	86.6%
ICHR	Ichor	3.0	38.0%	371.0%
NUVL	Nuvalent	9.7	35.5%	22.5%
CNTN	Canton Strategic	0.6	34.3%	2.0%
PAYO	Payoneer Global	2.3	33.9%	20.1%
ELVN	Enliven Therapeutics	2.9	32.9%	199.5%
GLXY	Galaxy Digital	6.4	32.7%	49.2%
UCTT	Ultra Clean	4.9	32.7%	329.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
PCT	PureCycle Technologies	1.6	-29.0%	3.4%
SMCI	Super Micro Computer	18.3	-26.8%	4.1%
SWMR	Swarmer	0.7	-25.6%	45.8%
WOLF	Wolfspeed	1.7	-21.6%	147.8%
NRGV	Energy Vault	0.7	-21.4%	-6.7%
MRLN	Merlin	0.5	-20.8%	-71.0%
SAIL	SailPoint	8.2	-19.8%	-27.7%
PRIM	Primoris Services	5.3	-19.0%	-20.5%
ADBE	Adobe	83.6	-18.9%	-41.7%
TMCR	Metals Royalty	0.5	-18.6%	-33.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
NVRI	Enviri	1.8	295.5%	329.9%
APPS	Digital Turbine	1.1	136.9%	95.2%
HYLN	Hyliion	1.3	106.1%	302.2%
AMC	AMC Entertainment	1.3	75.9%	50.0%
REPL	Replimune	0.8	67.5%	-8.6%
ALAB	Astera Labs	62.7	63.8%	120.7%
UMAC	Unusual Machines	0.9	63.2%	91.8%
GENI	Genius Sports	1.8	62.7%	-37.8%
DELL	Dell Technologies	261.1	62.2%	215.6%
CBRL	Cracker Barrel Old Country Store	1.0	61.3%	86.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
ADCT	ADC Therapeutics	0.2	-69.8%	-70.3%
VRRM	Verra Mobility	0.7	-65.2%	-79.2%
BTGO	BitGo	0.5	-58.2%	-73.1%
FULC	Fulcrum Therapeutics	0.3	-52.4%	-69.5%
LWLG	Lightwave Logic	1.4	-47.4%	196.0%
MRAM	Everspin Technologies	0.6	-41.1%	163.0%
HYMC	Hycroft Mining	2.3	-41.0%	8.4%
OMER	Omeros	0.6	-39.3%	-49.1%
JBIO	Jade Biosciences	0.9	-38.8%	-0.6%
PLAB	Photronics	1.8	-38.7%	-0.7%

Peer Comparisons

Peers to compare with:

Financials

	AKTS	LNTH	ATNM	CATX	LLY	BMY	Median
Name	Aktis On.	Lantheus	Actinium.	Perspect.	Eli Lilly	Bristol-.
Mkt Price	21.93	104.50	1.02	2.95	1,134.46	57.11	39.52
Mkt Cap	1.1	6.8	0.0	0.3	1,014.8	116.4	3.9
Rev LTM	7	1,546	0	0	72,250	48,483	777
Op Inc LTM	-74	290	-26	-120	34,172	13,591	132
FCF LTM	-80	372	-23	-107	10,368	11,908	174
FCF 3Y Avg	-	356	-32	-78	1,734	12,501	356
CFO LTM	-70	408	-23	-92	20,480	13,306	192
CFO 3Y Avg	-	419	-32	-53	11,158	13,780	419

Growth & Margins

	AKTS	LNTH	ATNM	CATX	LLY	BMY	Median
Name	Aktis On.	Lantheus	Actinium.	Perspect.	Eli Lilly	Bristol-.
Rev Chg LTM	-	0.6%	-	-	47.4%	1.8%	1.8%
Rev Chg 3Y Avg	-	15.4%	-	-	37.9%	1.9%	15.4%
Rev Chg Q	-	1.2%	-	-	55.5%	2.6%	2.6%
QoQ Delta Rev Chg LTM	75.9%	0.3%	0.0%	-	10.8%	0.6%	0.6%
Op Inc Chg LTM	-	-36.2%	48.1%	-58.7%	73.3%	72.7%	48.1%
Op Inc Chg 3Y Avg	-	512.9%	8.8%	-94.5%	67.4%	21.0%	21.0%
Op Mgn LTM	-987.8%	18.8%	-28,346.7%	-	47.3%	28.0%	18.8%
Op Mgn 3Y Avg	-	27.7%	-	-	39.7%	20.2%	27.7%
QoQ Delta Op Mgn LTM	451.3%	-1.7%	11,927.8%	-	1.7%	-0.4%	1.7%
CFO/Rev LTM	-933.0%	26.4%	-25,417.8%	-	28.3%	27.4%	26.4%
CFO/Rev 3Y Avg	-	28.1%	-	-	19.2%	29.2%	28.1%
FCF/Rev LTM	-1,068.5%	24.0%	-25,420.0%	-	14.4%	24.6%	14.4%
FCF/Rev 3Y Avg	-	23.9%	-	-	0.3%	26.5%	23.9%

Valuation

	AKTS	LNTH	ATNM	CATX	LLY	BMY	Median
Name	Aktis On.	Lantheus	Actinium.	Perspect.	Eli Lilly	Bristol-.
Mkt Cap	1.1	6.8	0.0	0.3	1,014.8	116.4	3.9
P/S	142.6	4.4	354.0	-	14.0	2.4	14.0
P/Op Inc	-14.4	23.3	-1.2	-2.5	29.7	8.6	3.7
P/EBIT	-14.4	17.2	-1.2	-2.7	28.4	10.2	4.5
P/E	-17.6	24.2	-1.4	-2.8	40.1	16.0	7.3
P/CFO	-15.3	16.6	-1.4	-3.3	49.5	8.7	3.7
Total Yield	-5.7%	4.1%	-74.4%	-36.4%	3.0%	10.6%	-1.3%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.6%	4.4%	0.0%
FCF Yield 3Y Avg	-	6.8%	-52.7%	-32.0%	0.2%	10.5%	0.2%
D/E	0.0	0.1	0.0	0.0	0.0	0.4	0.0
Net D/E	-0.5	0.0	-1.3	-0.9	0.0	0.3	-0.2

Returns

	AKTS	LNTH	ATNM	CATX	LLY	BMY	Median
Name	Aktis On.	Lantheus	Actinium.	Perspect.	Eli Lilly	Bristol-.
1M Rtn	12.5%	8.1%	-20.3%	-23.6%	12.9%	0.6%	4.3%
3M Rtn	15.5%	31.5%	-8.1%	-41.0%	15.4%	-2.3%	6.5%
6M Rtn	∞%	56.9%	-32.5%	10.5%	10.8%	11.4%	10.8%
12M Rtn	21,929,900.0%	34.3%	-31.5%	-6.9%	39.4%	20.5%	27.4%
3Y Rtn	598.4%	21.2%	-87.2%	-46.4%	158.8%	2.3%	11.7%
1M Excs Rtn	12.5%	8.5%	-20.8%	-22.6%	12.1%	1.4%	5.0%
3M Excs Rtn	3.4%	19.4%	-20.3%	-53.1%	3.3%	-14.4%	-5.5%
6M Excs Rtn	∞%	63.9%	-36.2%	7.8%	6.6%	6.1%	6.6%
12M Excs Rtn	21,929,876.6%	6.0%	-62.2%	-33.5%	17.9%	-3.8%	1.1%
3Y Excs Rtn	459.7%	-53.7%	-162.9%	-119.7%	91.3%	-73.4%	-63.6%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022
Period End	3/31/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022
Filing Date	5/11/2026	3/30/2026	1/9/2026	12/13/2024	12/13/2024
Key Financials
Total Revenue	7	6	1	0	0
Gross Profit	-	-	-	-	-
EBITDA	-72	-72	-50	-34	-19
Operating Income	-74	-75	-52	-35	-20
Net Income	-61	-64	-44	-29	-18
EPS	-1.44	-1.21	-1.26	-0.82	-0.51
Growth Rates
Total Revenue Growth	-	336.9%	∞%	-	-
EBITDA Growth	-	-43.3%	-50.2%	-73.9%	-
Operating Income Growth	-	-43.5%	-49.6%	-76.0%	-
Net Income Growth	-	-44.9%	-53.6%	-59.7%	-
Margins
Gross Margin	-	-	-	-	-
EBITDA Margin	-957.4%	-1113.7%	-3394.4%	-	-
Operating Income Margin	-987.8%	-1149.5%	-3500.3%	-	-
Net Income Margin	-809.2%	-980.9%	-2957.6%	-	-
Cash & Debt
Total Cash	538	227	297	98	129
Total Debt	12	12	12	13	2
Net Debt / (Cash)	-527	-215	-285	-84	-127
Cash Flows & CapEx
Net Cash from Operations	-70	-64	15	-30	-18
Total CapEx	-10	-10	-3	-4	-2
Free Cash from Operations	-80	-74	12	-34	-20
Returns to Shareholders
Dividends	0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1	2025Q4
Period End	3/31/2026	12/31/2025
Filing Date	5/11/2026	3/30/2026
Key Financials Quarterly
Total Revenue	3	2
Ebitda	-22	-17
Operating Income	-23	-17
Net Income	-18	-15
EPS	-0.38	-0.29
Key Financials TTM
Total Revenue TTM	7	4
Ebitda TTM	-72	-59
Operating Income TTM	-74	-61
Net Income TTM	-61	-51
Growth Rates Quarterly
Total Revenue Growth	-	-
EBITDA Growth	-128.4%	-
Operating Income Growth	-126.9%	-
Net Income Growth	-117.8%	-
Margins Quarterly
EBITDA Margin	-683.4%	-892.0%
Operating Income Margin	-703.6%	-929.1%
Net Income Margin	-567.9%	-809.5%
Cash & Debt
Total Cash	538	227
Total Debt	12	12
Net Debt / (Cash)	-527	-215
Cash Flows Quarterly
FCF from Operations	-24	-15
Cash Flows TTM
FCF from Operations TTM	-70	-53
Returns to Shareholders Quarterly
Dividends	0	0
Share Repurchases	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-58.9%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-47.9%	-

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022
Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor	6	0	0	0
Total	6	0	0	0

Net Income by Segment

$ Mil	2025	2024	2023
Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor	-64	-0	-0
Total	-64	-0	-0

Assets by Segment

$ Mil	2023	2022
Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor	0	0
Total	0	0

Price Behavior

Price Behavior

Market Price	$21.93
Market Cap ($ Bil)	1.1
First Trading Date	03/13/2017
Distance from 52W High	-2.1%
	50 Days	200 Days
DMA Price	$16.90	$9.75
DMA Trend	up	up
Distance from DMA	29.7%	125.0%
	3M	1YR
Volatility	73.4%	�
Downside Capture	283.69	�
Upside Capture	221.25	�
Correlation (SPY)	51.9%	�

AKTS Betas & Captures as of 5/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.67	1.90	2.57	0.27	�	�
Up Beta	0.66	1.46	2.34	0.19	�	�
Down Beta	-1.42	-0.20	4.30	-1.08	�	�
Up Capture	257%	186%	206%	169%	�	�
Bmk +ve Days	13	28	36	67	141	432
Stock +ve Days	11	25	36	49	55	253
Down Capture	317%	388%	238%	187%	�	�
Bmk -ve Days	7	13	27	57	109	318
Stock -ve Days	9	16	27	47	53	321

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AKTS
AKTS	-100.0%	213.4%	-1.90	-
Sector ETF (XLV)	15.4%	15.0%	0.74	11.5%
Equity (SPY)	24.9%	12.3%	1.52	19.1%
Gold (GLD)	25.5%	27.4%	0.81	6.4%
Commodities (DBC)	30.1%	19.0%	1.25	-6.2%
Real Estate (VNQ)	13.5%	13.5%	0.69	8.5%
Bitcoin (BTCUSD)	-41.7%	42.2%	-1.16	9.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AKTS
AKTS	-100.0%	197.8%	-0.93	-
Sector ETF (XLV)	6.4%	14.8%	0.25	11.7%
Equity (SPY)	13.5%	17.1%	0.61	17.2%
Gold (GLD)	16.8%	18.2%	0.75	3.3%
Commodities (DBC)	8.4%	19.4%	0.33	2.9%
Real Estate (VNQ)	2.8%	18.8%	0.05	16.2%
Bitcoin (BTCUSD)	13.6%	54.4%	0.44	5.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AKTS
AKTS	-100.0%	144.8%	-0.45	-
Sector ETF (XLV)	9.7%	16.6%	0.47	12.9%
Equity (SPY)	15.3%	17.9%	0.73	18.3%
Gold (GLD)	12.5%	16.1%	0.64	3.3%
Commodities (DBC)	6.7%	18.0%	0.29	5.3%
Real Estate (VNQ)	5.7%	20.7%	0.24	15.4%
Bitcoin (BTCUSD)	60.3%	66.8%	1.00	6.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	5292026
Short Interest: Shares Quantity	2.7 Mil
Short Interest: % Change Since 5152026	5.5%
Average Daily Volume	0.1 Mil
Days-to-Cover Short Interest	18.4 days
Basic Shares Quantity	48.6 Mil
Short % of Basic Shares	5.5%

Returns Analyses

null

Earnings Returns History

Updated 6/11/2026

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/11/2026	8.0%	1.9%	1.7%
SUMMARY STATS
# Positive	1	1	1
# Negative	0	0	0
Median Positive	8.0%	1.9%	1.7%
Median Negative
Max Positive	8.0%	1.9%	1.7%
Max Negative

	Forward Returns
5/11/2026	8.0%	1.9%	1.7%
SUMMARY STATS
# Positive	1	1	1
# Negative	0	0	0
Median Positive	8.0%	1.9%	1.7%
Median Negative
Max Positive	8.0%	1.9%	1.7%
Max Negative

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	05/11/2026	10-Q
12/31/2025	03/30/2026	10-K
09/30/2025	01/09/2026	424B4
09/30/2024	12/13/2024	DRS/A

Recent Forward Guidance

Updated 5/31/2026

Latest: null Earnings Reported 5/11/2026

null

Insider Activity

Updated 4/26/2026

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Ecor1, Capital, Llc	See Note	Buy	1122026	18.00	2,222,222	39,999,996	78,275,844	Form
2	Vida, Ventures Ii, Llc	See Footnote	Buy	1122026	18.00	835,000	15,030,000	102,092,850	Form
3	Kim, Helen Susan	See Footnote	Buy	1122026	18.00	835,000	15,030,000	102,092,850	Form

AKTS Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

Diversification Alternatives

How Is The Market Pricing AKTS?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What AKTS Makes & Who Pays

TTM figures based on

AKTS Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 6/13/2026

Aktis Oncology (AKTS)

Market Price (6/13/2026): $21.93 | Market Cap: $1.1 BilSector: Health Care | Industry: Biotechnology

Aktis Oncology (AKTS)

Market Price (6/13/2026): $21.93Market Cap: $1.1 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Aktis Oncology (AKTS)

Interactive Breakdown

Better Bets vs. Aktis Oncology (AKTS)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance

Insider Activity

AKTS Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

Diversification Alternatives

Repricing Catalyst

Market Price (6/13/2026): $21.93
Market Cap: $1.1 Bil
Sector: Health Care
Industry: Biotechnology